RAAS ANTAGONISTS TREATMENT AND ANGIOTENSINOGEN M235T AND T174M GENE POLYMORPHISMS IN HEART FAILURE PATIENTS
Abstract:
Two molecular variants of the angiotensinogen (AGT) gene, M235T and T174M, have been linked to an increased activity of the renin angiotensin aldosterone system (RAAS). Brain natriuretic peptide (BNP) is a severity marker for HF (HF). Objectives: We analyzed the association between the presence of these genotypes and the BNP fragment (8-29) level, and also studied the prescription rates of RAAS antagonists according to these mutations. Methods: There were analyzed 42 HF patients NYHA III- IV class, aged 65.76±76 years. Results: The mean value of serum BNP fragment was 2991.24±2034.61 fmol/ml. RAAS antagonists were prescribed as follows: ACE inhibitors in 71.42% of the patients; ARBS in 16.66% of the patients and aldosterone antagonists in 88.09% of the patients. Conclusion: We found no direct correlation between the AGT gene polymorphisms and BNP fragment level in our HF patients. RAAS antagonists are indicated in all HF patients, regardless the mutation present.
articol integral în limba engleză (.EN) |